Green Cross receives approval for quadrivalent influenza vaccine clinical test plan
Green Cross will begin clinical testing of a quadrivalent influenza vaccine within the year using cell culture technology
YONGIN, Korea I March 28, 2014 I Green Cross (President Soon-tae Cho) announced on the 28th that a clinical testing plan for Phase 1/2a of quadrivalent influenza vaccine development has been approved by the Ministry of Food and Drug Safety.
A quadrivalent influenza vaccine can offer immunity to 4 types of influenza virus in a single vaccination.
The vaccine currently distributed in Korea is a trivalent influenza vaccine offering protecting against 3 strains of influenza. It is generally known that a trivalent influenza vaccine is enough to provide adequate immunity, but recently quadrivalent influenza vaccinations have been recommended to offer more extensive protection in preparation to ward off a pandemic caused by mutated strains of influenza.
“The quadrivalent vaccine will soon undergo clinical testing, implementing the traditional method using fertile eggs,” said a Green Cross official. “We also plan to initiate clinical testing of a quadrivalent vaccine within the year, using cell culture technology.”
Cell culture technology is a new technology culturing viruses via animal cells and turning them into vaccines. This new method has higher production costs, but a shorter production period, thus ensuring a stable supply despite emergent crises, such as that presented by Avian Influenza, or AI.
In 2009 Green Cross was the first group in Korea to succeed in developing an influenza vaccine, illustrating its outstanding technological skills in the global influenza vaccine market, on par with top pharmaceutical companies worldwide. Only four companies around the world, including Green Cross, hold qualifications to participate in influenza vaccine bidding by the World Health Organization (WHO), and Green Cross is the only one operating in Asia.
SOURCE: Green Cross
Post Views: 193
Green Cross receives approval for quadrivalent influenza vaccine clinical test plan
Green Cross will begin clinical testing of a quadrivalent influenza vaccine within the year using cell culture technology
YONGIN, Korea I March 28, 2014 I Green Cross (President Soon-tae Cho) announced on the 28th that a clinical testing plan for Phase 1/2a of quadrivalent influenza vaccine development has been approved by the Ministry of Food and Drug Safety.
A quadrivalent influenza vaccine can offer immunity to 4 types of influenza virus in a single vaccination.
The vaccine currently distributed in Korea is a trivalent influenza vaccine offering protecting against 3 strains of influenza. It is generally known that a trivalent influenza vaccine is enough to provide adequate immunity, but recently quadrivalent influenza vaccinations have been recommended to offer more extensive protection in preparation to ward off a pandemic caused by mutated strains of influenza.
“The quadrivalent vaccine will soon undergo clinical testing, implementing the traditional method using fertile eggs,” said a Green Cross official. “We also plan to initiate clinical testing of a quadrivalent vaccine within the year, using cell culture technology.”
Cell culture technology is a new technology culturing viruses via animal cells and turning them into vaccines. This new method has higher production costs, but a shorter production period, thus ensuring a stable supply despite emergent crises, such as that presented by Avian Influenza, or AI.
In 2009 Green Cross was the first group in Korea to succeed in developing an influenza vaccine, illustrating its outstanding technological skills in the global influenza vaccine market, on par with top pharmaceutical companies worldwide. Only four companies around the world, including Green Cross, hold qualifications to participate in influenza vaccine bidding by the World Health Organization (WHO), and Green Cross is the only one operating in Asia.
SOURCE: Green Cross
Post Views: 193
